Characterization and quantitative estimation of activated cyclophosphamide in blood and urine
- PMID: 872087
Characterization and quantitative estimation of activated cyclophosphamide in blood and urine
Abstract
An assay for the characterization and quantitative determination of activated cyclophosphamide has been described. The method is based on high reactivity of the kryptaldehyde group in 4-hydroxycyclophosphamide with mercapto compounds to yield 4-(S-R)mercaptocyclophosphamide derivatives. The activated cyclophosphamide can be converted quantitatively to 4-(S-benzyl)mercaptocyclophosphamide with benzyl mercaptan, and the mercapto derivative can be separated by thin-layer chromatography on silica gel with ethyl acetate:methyl ethyl ketone as solvent. Using this assay, significant levels of activated cyclophosphamide in the blood of mice and rats, as well as of humans, were found to be present after cyclophosphamide application. The characterization of 4-(S-benzyl)mercaptocyclophosphamide formed was confirmed by comparing the thin-layer chromatographic and mass spectrometric data on this derivative obtained from an authentic sample of 4-hydroxycyclophosphamide.
Similar articles
-
Studies on 4-hydroperoxycyclophosphamide (NSC-181815): a simple preparation method and its application for the synthesis of a new class of "activated" sulfur-containing cyclophosphamide (NSC-26271) derivatives.Cancer Treat Rep. 1976 Apr;60(4):429-35. Cancer Treat Rep. 1976. PMID: 1277218
-
[Quantitative determination of cyclophosphamide, ifosfamide, and trofosfamide and their stable metabolites on TLC-plates with the aid of 4-pyridine-aldehyde-2-benzothiazolyl-hydrazone (PBH) (author's transl)].Arzneimittelforschung. 1975 Sep;25(9):1331-6. Arzneimittelforschung. 1975. PMID: 1242654 German.
-
Identification and pharmacokinetics of cyclophosphamide (NSC-26271) metabolites in vivo.Cancer Treat Rep. 1976 Apr;60(4):415-22. Cancer Treat Rep. 1976. PMID: 1277216
-
Analysis of 4-hydroxycyclophosphamide in human blood.Anal Biochem. 1995 Jan 1;224(1):154-8. doi: 10.1006/abio.1995.1021. Anal Biochem. 1995. PMID: 7710063
-
Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.Drug Metab Dispos. 1997 May;25(5):544-51. Drug Metab Dispos. 1997. PMID: 9152592
Cited by
-
Metformin inhibits metastatic breast cancer progression and improves chemosensitivity by inducing vessel normalization via PDGF-B downregulation.J Exp Clin Cancer Res. 2019 Jun 4;38(1):235. doi: 10.1186/s13046-019-1211-2. J Exp Clin Cancer Res. 2019. PMID: 31164151 Free PMC article.
-
Resistance of human T-CFUcs to activated cyclophosphamide: a feature common with critical marrow stem cells?Br J Cancer. 1985 Sep;52(3):403-5. doi: 10.1038/bjc.1985.208. Br J Cancer. 1985. PMID: 3876106 Free PMC article. No abstract available.
-
Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.Clin Pharmacokinet. 2001 Jan;40(1):41-62. doi: 10.2165/00003088-200140010-00004. Clin Pharmacokinet. 2001. PMID: 11236809 Review.
-
[On the binding of cyclophosphamide and cyclophosphamide-metabolites to serum-albumin (author's transl)].Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1978 May 31;91(2):127-42. doi: 10.1007/BF00284020. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1978. PMID: 27021 German. No abstract available.
-
[Fluorometric determination of "activated" cyclophosphamide and ifosfamide in blood (author's transl)].J Cancer Res Clin Oncol. 1979 Apr 12;93(3):233-40. doi: 10.1007/BF00964578. J Cancer Res Clin Oncol. 1979. PMID: 468886 German.